Edwards Lifesciences Corp (NYSE:EW) Shares Acquired by Pacer Advisors Inc.

Pacer Advisors Inc. lifted its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 10.2% during the third quarter, Holdings Channel.com reports. The fund owned 23,038 shares of the medical research company’s stock after purchasing an additional 2,129 shares during the period. Pacer Advisors Inc.’s holdings in Edwards Lifesciences were worth $5,066,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of EW. Nuveen Asset Management LLC increased its stake in shares of Edwards Lifesciences by 8,278.5% during the second quarter. Nuveen Asset Management LLC now owns 3,951,568 shares of the medical research company’s stock valued at $730,013,000 after acquiring an additional 3,904,405 shares during the period. FMR LLC boosted its holdings in Edwards Lifesciences by 7.9% during the first quarter. FMR LLC now owns 8,175,796 shares of the medical research company’s stock worth $1,564,274,000 after buying an additional 598,976 shares in the last quarter. Bessemer Group Inc. boosted its holdings in Edwards Lifesciences by 56,300.0% during the second quarter. Bessemer Group Inc. now owns 503,652 shares of the medical research company’s stock worth $93,045,000 after buying an additional 502,759 shares in the last quarter. Marshall Wace North America L.P. boosted its stake in Edwards Lifesciences by 394.9% in the 2nd quarter. Marshall Wace North America L.P. now owns 364,492 shares of the medical research company’s stock worth $67,336,000 after purchasing an additional 290,838 shares during the period. Finally, Jennison Associates LLC boosted its stake in Edwards Lifesciences by 4.8% in the 2nd quarter. Jennison Associates LLC now owns 6,039,006 shares of the medical research company’s stock worth $1,115,646,000 after purchasing an additional 275,182 shares during the period. Institutional investors and hedge funds own 81.53% of the company’s stock.

A number of equities analysts recently commented on EW shares. Citigroup set a $159.00 price objective on shares of Edwards Lifesciences and gave the stock a “sell” rating in a research note on Friday, July 26th. Jefferies Financial Group raised their price objective on shares of Edwards Lifesciences from $210.00 to $245.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Morgan Stanley raised their price objective on shares of Edwards Lifesciences from $210.00 to $228.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 24th. Wells Fargo & Co raised their price objective on shares of Edwards Lifesciences from $220.00 to $250.00 and gave the stock an “outperform” rating in a research note on Friday, September 6th. Finally, Credit Suisse Group raised their price objective on shares of Edwards Lifesciences from $221.00 to $226.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Two analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $213.33.

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 1,152 shares of Edwards Lifesciences stock in a transaction on Monday, July 15th. The shares were sold at an average price of $191.70, for a total transaction of $220,838.40. Following the completion of the sale, the vice president now owns 19,162 shares of the company’s stock, valued at approximately $3,673,355.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William J. Phd Link sold 10,214 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $221.86, for a total transaction of $2,266,078.04. Following the sale, the director now directly owns 16,817 shares of the company’s stock, valued at approximately $3,731,019.62. The disclosure for this sale can be found here. Insiders have sold a total of 155,822 shares of company stock valued at $33,641,784 in the last three months. Company insiders own 1.63% of the company’s stock.

Shares of NYSE:EW opened at $227.11 on Friday. The firm has a fifty day moving average of $219.92 and a two-hundred day moving average of $197.32. The firm has a market capitalization of $47.23 billion, a P/E ratio of 48.32, a price-to-earnings-growth ratio of 2.83 and a beta of 0.84. Edwards Lifesciences Corp has a 12-month low of $136.44 and a 12-month high of $230.19. The company has a quick ratio of 2.48, a current ratio of 3.38 and a debt-to-equity ratio of 0.18.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.05. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.04 billion. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The company’s revenue for the quarter was up 15.2% on a year-over-year basis. During the same quarter last year, the business posted $1.24 EPS. Equities research analysts expect that Edwards Lifesciences Corp will post 5.34 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: What is the return on assets formula?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.